Remove Assay Development Remove Drug Development Remove Laboratories
article thumbnail

Highlights From the 2025 American Society for Mass Spectrometry Conference | By Jean-François Larocque and Benjamin Charron

Alta Sciences

Following clear processes, in accordance with GLP and current FDA/EMA guidelines—and supported by our unique array of platforms and large list of validated assays —our team ensures the most effective methods for your individual programs. We have state-of-the-art, purpose-built laboratories at our locations in the U.S.

article thumbnail

Six Factors for Biotech Companies to Consider When Choosing Next-Generation Contract GMP/CMC Laboratories

PPD

1 With this growth comes increased demands for laboratory services at all steps across the development process. Access to a laboratory partner that already possesses the equipment, knowledge and personnel can save time and money. For rapid expansion of late-stage assay platforms, speed and a proven track record are pivotal.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Target-directed cancer: protein-ligand interactions  

Drug Target Review

We support the drug discovery projects of the CCDD with assay development and screening, biophysics, structural biology and recombinant protein production. Both of the ICR’s research laboratory sites in Sutton and in Chelsea are in close proximity to the Royal Marsden Hospital sites.

article thumbnail

The essential role of recombinant phage display antibody libraries

Drug Target Review

In 2024 alone, almost 50 antibody drug candidates are anticipated to enter regulatory review, the majority of which are mAbs. Aside from the advent of complex antibody-based drugs, the industry is facing some additional changes which are shaping drug development. Adapted from Harth S et al. (8) 8) under a CC BY-NC-ND 4.0.